DoD Peer Reviewed, Impact Award | W81XWH 22 PRCRP IPA

Opportunity Information: Apply for W81XWH 22 PRCRP IPA

The DoD Peer Reviewed Cancer Research Program (PRCRP) FY22 Impact Award is a Department of Defense funding opportunity designed to support hypothesis-driven cancer research that is mature, clinically oriented, and positioned to produce a major near-term payoff. Rather than backing early exploratory ideas, this mechanism is meant for projects that already have a strong foundation and are ready to move promising findings closer to real-world use, such as improved treatments, prevention approaches, or other strategies that can affect patient outcomes in the near future. A central goal is to build momentum in underfunded, understudied, and/or particularly lethal cancers and research areas that are also relevant to military health needs.

A defining expectation of the Impact Award is clear, substantial impact that goes beyond incremental progress. Applicants need to show how their work could meaningfully transform cancer research or clinical care in at least one of the FY22 PRCRP Topic Areas and also address at least one of the program's overarching challenges (as referenced in the full announcement). The program explicitly welcomes translational and clinical research, including clinical trials, as long as the proposal makes a strong case that the results are likely to matter on a near-term timeline. In other words, this is not a basic research mechanism; proposals that are primarily fundamental biology or that only imply distant, long-range clinical benefit are directed instead to the FY22 PRCRP Idea Award.

Another key requirement is the use of preliminary data. The award is intended to "leapfrog" the field by building directly on prior findings, so applications must include evidence that the approach is feasible and ready for a more definitive, high-impact study. If unpublished preliminary data are included, they are expected to come from the Principal Investigator's laboratory or from a member of the project team, reinforcing the idea that the team has already generated credible signals and is prepared to execute the next step.

Continuity of research is a major review factor. The DoD is looking for established lines of investigation that have progressed beyond basic discovery and are now poised to influence clinical research or clinical practice. This often implies the project can leverage clinical samples, existing datasets, and/or ongoing or planned clinical trials to accelerate translation. Proposals that make effective use of these resources and show a realistic path to patient-relevant outcomes align strongly with the intent of the mechanism.

Rigor in evaluation is also emphasized. Applicants are expected to present a solid statistical plan and a clear data analysis strategy that match the patient-centered, near-term nature of the program. The review focus is not only whether the science is interesting, but whether the study is designed tightly enough to generate results that can stand up to scrutiny and meaningfully inform clinical decisions, future trials, or implementation of preventive or therapeutic strategies.

Administratively, this opportunity was released by the Department of Defense (Department of the Army, USAMRAA) under Funding Opportunity Number W81XWH-22-PRCRP-IPA. Funding instruments include grants and cooperative agreements, and eligibility is described as unrestricted (open broadly to many entity types, subject to any specific clarifications in the announcement). The original posting date was March 31, 2022, with an original closing date of September 7, 2022. The listing indicated an expected 16 awards, and it did not specify a formal award ceiling in the provided summary.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed, Impact Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 31, 2022.
• Applicants must submit their applications by Sep 07, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 16 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PRCRP IPA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: